ORENCIA® (ABATACEPT) INJECTION
FOR INTRAVENOUS INFUSION

Policy Number: PHARMACY 199.13 T2

Effective Date: November 1, 2017

Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSTRUCTIONS FOR USE</td>
</tr>
<tr>
<td>CONDITIONS OF COVERAGE</td>
</tr>
<tr>
<td>BENEFIT CONSIDERATIONS</td>
</tr>
<tr>
<td>COVERAGE RATIONALE</td>
</tr>
<tr>
<td>U.S. FOOD AND DRUG ADMINISTRATION</td>
</tr>
<tr>
<td>BACKGROUND</td>
</tr>
<tr>
<td>APPLICABLE CODES</td>
</tr>
<tr>
<td>CLINICAL EVIDENCE</td>
</tr>
<tr>
<td>REFERENCES</td>
</tr>
<tr>
<td>POLICY HISTORY/REVISION INFORMATION</td>
</tr>
</tbody>
</table>

INSTRUCTIONS FOR USE

This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies.

When deciding coverage, the member specific benefit plan document must be referenced. The terms of the member specific benefit plan document [e.g., Certificate of Coverage (COC), Schedule of Benefits (SOB), and/or Summary Plan Description (SPD)] may differ greatly from the standard benefit plan upon which this Clinical Policy is based. In the event of a conflict, the member specific benefit plan document supersedes this Clinical Policy. All reviewers must first identify member eligibility, any federal or state regulatory requirements, and the member specific benefit plan coverage prior to use of this Clinical Policy. Other Policies may apply.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

CONDITIONS OF COVERAGE

| Applicable Lines of Business/ Products | This policy applies to Oxford Commercial plan membership. |
| Benefit Type | General Benefits Package |
| Referral Required (Does not apply to non-gatekeeper products) | No |
| Authorization Required (Precertification always required for inpatient admission) | Yes¹,² |
| Precertification with Medical Director Review Required | Yes¹,² |
| Applicable Site(s) of Service (If site of service is not listed, Medical Director review is required) | All¹,² |

¹Precertification through Oxford’s Medical Management Department (with review by a Medical Director or their designee) is required for Orencia intravenous infusion.

Note: New Jersey Small Members should refer to their certificate of coverage for precertification and quantity

Related Policies

- Acquired Rare Disease Drug Therapy Exception Process
- Drug Coverage Guidelines
- Specialty Medication Administration – Site of Care Review Guidelines
Special Considerations (continued)

2 Precertification is encouraged (but not required) for out-of-network services covered under the general benefits package when provided in a physician's office. If precertification is not obtained, Oxford may review for medical necessity after the service is rendered.

BENEFIT CONSIDERATIONS

Before using this policy, please check the member specific benefit plan document and any federal or state mandates, if applicable.

Some Certificates of Coverage allow coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the member specific benefit plan document or in the medical or drug policy. Benefit coverage for an otherwise unproven service for the treatment of serious rare diseases may occur when certain conditions are met; refer to the policy titled Acquired Rare Disease Drug Therapy Exception Process.

Essential Health Benefits for Individual and Small Group

For plan years beginning on or after January 1, 2014, the Affordable Care Act of 2010 (ACA) requires fully insured non-grandfathered individual and small group plans (inside and outside of Exchanges) to provide coverage for ten categories of Essential Health Benefits (“EHBs”). Large group plans (both self-funded and fully insured), and small group ASO plans, are not subject to the requirement to offer coverage for EHBs. However, if such plans choose to provide coverage for benefits which are deemed EHBs, the ACA requires all dollar limits on those benefits to be removed on all Grandfathered and Non-Grandfathered plans. The determination of which benefits constitute EHBs is made on a state by state basis. As such, when using this policy, it is important to refer to the member specific benefit plan document to determine benefit coverage.

COVERAGE RATIONALE

This policy refers to Orencia (abatacept) injection for intravenous infusion.

Orencia is proven and medically necessary for the treatment of:

- Polyarticular juvenile idiopathic arthritis when all of the following criteria are met:2,5,15,20
  - Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis (PJIA); and
  - Orencia is initiated and titrated according to US Food and Drug Administration labeled dosing for polyarticular juvenile idiopathic arthritis up to a maximum of (or equivalent dose and interval schedule):
    - 10mg/kg every 4 weeks for patients weighing <75kg
    - 1,000mg every 4 weeks for patients weighing ≥75kg
  and
  - Member is not receiving Orencia in combination with either of the following:
    - Biologic disease-modifying antirheumatic drug (DMARD) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
    - Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]

- Rheumatoid arthritis when all of the following criteria are met:1,5,15,16,21
  - Diagnosis of moderately to severely active rheumatoid arthritis; and
  - Orencia is initiated and titrated according to US Food and Drug Administration labeled dosing for rheumatoid arthritis up to a maximum of (or equivalent dose and interval schedule):
    - 500mg every 4 weeks for patients weighing <60kg
    - 750mg every 4 weeks for patients weighing 60kg to 100kg
    - 1,000mg every 4 weeks for patients weighing >100kg
  and
  - Member is not receiving Orencia in combination with either of the following:
    - Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
    - Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]

- Psoriatic arthritis when all of the following criteria are met:
  - Diagnosis of active psoriatic arthritis (PsA); and
Orencia® (Abatacept) Injection for Intravenous Infusion

UnitedHealthcare Oxford Clinical Policy

©1996-2017, Oxford Health Plans, LLC

Page 3 of 9
Effective 11/01/2017

Orencia is initiated and titrated according to US Food and Drug Administration labeled dosing for psoriatic arthritis up to a maximum of (or equivalent dose and interval schedule):
- 500mg every 4 weeks for patients weighing <60kg
- 750mg every 4 weeks for patients weighing 60kg to 100kg
- 1,000mg every 4 weeks for patients weighing >100kg

and

- Patient is not receiving Orencia in combination with any of the following:
  - Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
  - Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
  - Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

Orencia is unproven and not medically necessary for the treatment of:
- Multiple sclerosis
- Systemic lupus erythematosus
- Graft versus host disease (GVHD)
- Uveitis associated with Behçet’s disease

U.S. FOOD AND DRUG ADMINISTRATION (FDA)

Orencia intravenous infusion is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Abatacept may be used as monotherapy or concomitantly with DMARDs other than tumor necrosis factor (TNF) antagonists.

Orencia is also indicated for reducing signs and symptoms in pediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis. Abatacept may be used as monotherapy or concomitantly with methotrexate. Orencia is also indicated for the treatment of adult patients with active psoriatic arthritis.

The labeling for Orencia states that it should not be administered concomitantly with TNF antagonists or with other biologic RA therapy, such as Kineret (anakinra), an interleukin-1 receptor antagonist. In controlled clinical trials in patients with adult RA, patients receiving concomitant Orencia and TNF antagonist therapy experienced more infections (63%) and serious infections (4.4%) compared to patients treated with only TNF antagonists (43% and 0.8%, respectively). These trials failed to demonstrate superiority of results with concomitant administration of Orencia and TNF antagonists. Therefore, clinical evidence does not support concurrent therapy with Orencia and TNF antagonists.

BACKGROUND

Orencia is a fully human, soluble, fusion protein, selective co-stimulation modulator which inhibits T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. This interaction provides a co-stimulatory signal necessary for full activation of T lymphocytes.

APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0129</td>
<td>Injection, abatacept, 10 mg [Orencia] (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)</td>
</tr>
</tbody>
</table>

ICD-10 Diagnosis Code

| | 
|---|---
| | Orencia ICD-10 Diagnosis Codes |
**Proven/Medically Necessary**

**Psoriatic Arthritis**
A randomized, placebo controlled Phase 3 trial assessed the efficacy and safety of abatacept in adult patients (>18 years old) with psoriatic arthritis. Patients were randomly assigned in a double-blind manner to receive either subcutaneous abatacept 125mg weekly or placebo for 24 weeks. Patients who had not achieved ≥20% improvement in swollen and tender joint counts from baseline to week 16 were switched to open-label abatacept weekly for 28 weeks. At the end of the open-label period, patients had the option of entering a 1 year, long-term extension. Primary efficacy endpoint was the proportion of patients with ACR20 responses at week 24. Abatacept significantly increased ACR20 response versus placebo at week 24 (39.4% vs 22.3%; p<0.001). Although abatacept numerically increased Health Assessment Questionnaire–Disability Index response rates (reduction from baseline ≥0.35) at week 24, this was not statistically significant (31.0% vs 23.7%; p=0.097). The benefits of abatacept were seen in ACR20 responses regardless of TNF inhibitor exposure and in other musculoskeletal manifestations, but significance could not be attributed due to ranking below Health Assessment Questionnaire–Disability Index response in hierarchical testing. The benefit on psoriasis lesions was modest. Efficacy was maintained or improved up to week 52. Abatacept was well tolerated with no new safety signals. The authors concluded that abatacept treatment of PsA in achieved its primary end point, ACR20 response, showed beneficial trends overall in musculoskeletal manifestations and was well tolerated. There was only a modest impact on psoriasis lesions.

**Rheumatoid Arthritis**
A randomized, multicenter, active controlled Phase 3b trial, the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial (n=351) of 24 months, with a 12-month, double-blind treatment period, evaluated clinical remission with subcutaneous abatacept plus methotrexate (MTX) and abatacept monotherapy in patients with early rheumatoid arthritis (RA), and maintenance of remission following the rapid withdrawal of all RA treatment.17 During the 12 month treatment period, patients were randomized (1:1:1) to receive abatacept plus MTX (n=119), abatacept monotherapy (n=116), or MTX monotherapy (n=116), stratified by corticosteroid use at baseline. Patients with a Disease Activity Score (DAS)28 (CRP) <3.2 at month 12 could enter the 12 month withdrawal period where abatacept was immediately stopped and MTX and steroids tapered over 1 month. Patients with DAS28 ≥3.2 discontinued the study. After month 15, patients in the withdrawal period who experienced a flare could re-start open label SC abatacept 125mg plus MTX. Co-primary endpoints were the proportion of randomized and treated patients in DAS-defined remission (CRP <2.6) at month 12 and months 12 and 18 for abatacept plus MTX versus MTX. For the abatacept plus MTX versus MTX, DAS28 (CRP) <2.6 was achieved in 60.9% versus 45.2% (p=0.010) at 12 months, and following treatment withdrawal, in 14.8% versus 7.8% (p=0.045) at both 12 and 18 months. DAS28 (CRP) <2.6 was achieved for abatacept monotherapy in 42.5% (month 12) and 12.45% (both months 12 and 18). Both abatacept arms had a safety profile comparable to MTX alone. The authors concluded that abatacept plus MTX demonstrated efficacy compared with MTX alone in early RA, with a comparable safety profile to MTX. Abatacept achieved some sustained remission following withdrawal of all RA therapy in the respective groups.

**Polyarticular Juvenile Idiopathic Arthritis**
The long-term extension (LTE) phase of a pivotal phase III study examining the efficacy and safety of abatacept in patients with juvenile idiopathic arthritis (JIA) reported the efficacy and safety outcomes of treatment (up to 10mg/kg every 4 weeks), with or without non-biologic DMARDs, for up to 7 years of follow-up.19 One hundred fifty-three of 190 patients (80.5%) entered the LTE phase, with only 69 patients (36.3%) completing the study. The overall incidence rate (events per 100 patient-years) of adverse events decreased from 433.61 events during the short-term phase compared to 132.39 events during the LTE phase. Serious adverse events (6.82 vs. 5.60), malignancies (1.12 vs. 0), and autoimmune events (2.26 vs. 1.18) also were reduced. Serious infections were slightly increased (1.13 vs. 1.72). American College of Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 70, responses, and clinically inactive disease status were maintained throughout the extension phase in those patients continuing to receive therapy. Improvements in the Child Health Questionnaire summary scores were also maintained over the course of the study. The authors concluded that long-term abatacept therapy, for up to 7 years, was associated with consistent safety, efficacy, and quality of life benefits in patients with JIA.

**Unproven/Not Medically Necessary**

**Multiple Sclerosis**
A randomized, double-blind, placebo-controlled Phase II study of 128 patients was initiated to evaluate the use of abatacept in patients with relapsing-remitting multiple sclerosis.8 The primary objective was to demonstrate the relative safety and preliminary clinical efficacy of 2 different doses of abatacept (10 mg/kg and 2 mg/kg) compared with placebo in subjects with relapsing-remitting MS by showing a reduction in the cumulative number of new or recurrent gadolinium-enhancing lesions on T1-weighted (Gd-T1) magnetic resonance imaging (MRI) over Day 85 through Day 225. However, the study terminated early because the Drug Safety Monitoring Board (DSMB) responsible
for reviewing blinded safety data from the study expressed concerns that one of the treatment groups (subsequently found to be the 2 mg/kg abatacept group) had more subjects exhibiting an increase in Gd-enhancing T1-weighted MRI lesions and at least 1 multiple sclerosis exacerbation.

**Systemic Lupus Erythematosus**

A Phase II multi-center, randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy and safety of abatacept (n=121) versus placebo (n=59) for patients with systemic lupus erythematosus (SLE). The abatacept group received the study drug (weight-tiered dosing) administered intravenously on Day 1, 15, 29, and every 28 days thereafter. Planned treatment duration for the double-blind period was 12 months. Prednisone or prednisone equivalent oral tablets was given on a defined tapering schedule at the time of randomization along with the study medication or placebo. The study failed to meet the primary efficacy endpoint, which was to assess the proportion of subjects who experienced a new SLE flare, based on adjudication of all BILAG 'A' or 'B' events, following resolution of the entry flare and/or the start of prednisone or prednisone equivalent taper schedule across the 12-month double-blind treatment period.

**Graft Versus Host Disease (GVHD), Psoriatic Arthropathy, and Uveitis Associated with Behçet's Disease**

Blockade of antigen non-specific co-stimulatory signals is theorized to be effective for conditions such as GVHD, psoriatic arthropathy, and Behçet's disease. However, there is currently insufficient clinical evidence of the safety and efficacy of abatacept in published peer-reviewed medical literature for these conditions.

**Professional Societies**

**Rheumatoid Arthritis**

The 2015 American College of Rheumatology (ACR) RA treatment guideline addresses the use of DMARDS, biologics, tofacitinib, and glucocorticoids in early (<6 months) and established (≥ 6 months) RA and the use of various treatment approaches in frequently encountered clinical scenarios, including treat-to-target, switching between therapies, tapering of therapy, the use of biologics and DMARDS in high-risk RA patients, vaccination in patients with RA receiving DMARDS or biologics, TB screening with biologics or tofacitinib, and laboratory monitoring with DMARDS. The guideline recommendations apply to common clinical situations, since the panel considered issues common to most patients, not exceptions. Recommendations are classified as either strong or conditional. A strong recommendation means that the panel was confident that the desirable effects of following the recommendation outweigh the undesirable effects (or vice versa), so the course of action would apply to most patients, and only a small proportion would not want to follow the recommendation. A conditional recommendation means that the desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of patients, but some may not want to follow the recommendation. As a result, conditional recommendations are preference sensitive and warrant a shared decision-making approach.

Supplementary Appendix 5, of the 2015 ACR RA guideline, summarizes recommendations for patients with early RA, established RA, and high-risk comorbidities.

**Recommendations for Early RA Patients**

- The panel strongly recommends using a treat-to-target strategy rather than a non-targeted approach, regardless of disease activity level. The ideal target should be low disease activity or remission, as determined by the clinician and the patient. In some cases, another target may be chosen because risk tolerance by patients or comorbidities may mitigate the usual choices.
- For DMARD-naïve patients with early, symptomatic RA, the panel strongly recommends DMARD monotherapy over double or triple DMARD therapy in patients with low disease activity and conditionally recommends DMARD monotherapy over double or triple DMARD therapy in patients with moderate or high disease activity. Methotrexate should be the preferred initial therapy for most patients with early RA with active disease.
- For patients with moderate or high disease activity despite DMARD therapy (with or without glucocorticoids), the panel strongly recommends treatment with a combination of DMARDS or a TNFi or a non-TNF biologic, with or without methotrexate (MTX) in no particular order of preference, rather than continuing DMARD monotherapy alone. Biologic therapy should be used in combination with MTX over biologic monotherapy, when possible, due to superior efficacy.
- For patients with moderate or high disease activity despite any of the above DMARD or biologic therapies, the panel conditionally recommends adding low-dose glucocorticoids (defined as ≤10 mg/day of prednisone or equivalent). Low-dose glucocorticoids may also be used in patients who need a bridge until realizing the benefits of DMARD therapy. The risk/benefit ratio of glucocorticoid therapy is favorable as long as the dose is low and the duration of therapy is short.
- For patients experiencing a flare of RA, the panel conditionally recommends adding short-term glucocorticoids (< 3 months of treatment) at the lowest possible dose for the shortest possible duration, to provide a favorable benefit-risk ratio for the patient.
Recommendations for Established RA Patients

- The panel strongly recommends using a treat-to-target strategy rather than a non-targeted approach, regardless of disease activity level. The ideal target should be low disease activity or remission, as determined by the clinician and the patient. In some cases, however, another target may be chosen because tolerance by patients or comorbidities may mitigate the usual choices.

- For DMARD-naive patients with low disease activity, the panel strongly recommends using DMARD monotherapy over a TNFi. For DMARD-naive patients with moderate or high disease activity, the panel conditionally recommends DMARD monotherapy over double or triple DMARD therapy and DMARD monotherapy over tofacitinib.

In general, MTX should be the preferred initial therapy for most patients with established RA with active disease.

- For patients with moderate or high disease activity despite DMARD monotherapy including methotrexate, the panel strongly recommends using combination DMARDs or adding a TNFi or a non-TNF biologic or tofacitinib (all choices with or without methotrexate) in no particular order of preference, rather than continuing DMARD monotherapy alone. Biologic therapy should be used in combination with MTX over biologic monotherapy, when possible, due to its superior efficacy.

For all scenarios for established RA below, treatment may be with or without MTX

- For moderate or high disease activity despite TNFi therapy in patients currently not on a DMARD, the panel strongly recommends that one or two DMARDs be added to TNFi therapy rather than continuing TNFi therapy alone.

- If disease activity is moderate or high despite single TNFi biologic therapy, the panel conditionally recommends using a non-TNF biologic.

- If disease activity is moderate or high despite non-TNF biologic therapy, the panel conditionally recommends using another non-TNF biologic. However, if a patient has failed multiple non-TNF biologics and they are TNFi-naive with moderate or high disease activity, the panel conditionally recommends treatment with a TNFi.

- For patients with moderate or high disease activity despite prior treatment with at least one TNFi and at least one non-TNF-biologic (sequentially, not combined), the panel conditionally recommends first treating with another non-TNF biologic. However, when a non-TNF biologic is not an option (e.g., patient declines non-TNF biologic therapy due to inefficacy or side effects), the panel conditionally recommends treatment with tofacitinib.

- If disease activity is moderate or high despite the use of multiple (2+) TNFi therapies (in sequence, not concurrently), the panel conditionally recommends non-TNF biologic therapy and then conditionally treating with tofacitinib when a non-TNF biologic is not an option.

- If disease activity is moderate or high despite any of the above DMARD or biologic therapies, the panel conditionally recommends adding low-dose glucocorticoids.

- If patients with established RA experience an RA flare while on DMARD, TNFi, or non-TNF biologic therapy, the panel conditionally recommends adding short-term glucocorticoids (< 3 months of treatment) at the lowest possible dose and for shortest possible duration to provide the best benefit-risk ratio for the patient.

- In patients with established RA and low disease activity but not remission, the panel strongly recommends continuing DMARD therapy, TNFi, non-TNF biologic or tofacitinib rather than discontinuing respective medication.

- In patients with established RA currently in remission, the panel conditionally recommends tapering DMARD therapy, TNFi, non-TNF biologic, or tofacitinib.

- The panel strongly recommends not discontinuing all therapies in patients with established RA in disease remission.

Recommendations for RA Patients with High-Risk Comorbidities

Congestive Heart Failure

- In patients with established RA with moderate or high disease activity and New York Heart Association (NYHA) class III or IV congestive heart failure (CHF), the panel conditionally recommends using combination DMARD therapy, a non-TNF biologic, or tofacitinib rather than a TNFi.

- If patients in this population are treated with a TNFi and their CHF worsens while on the TNFi, the panel conditionally recommends switching to combination DMARD therapy, a non-TNF biologic, or tofacitinib rather than a different TNFi.

Hepatitis B

- In patients with established RA with moderate or high disease activity and evidence of active hepatitis B infection (hepatitis surface antigen positive > 6 months), who are receiving or have received effective antiviral treatment, the panel strongly recommends treating them the same as patients without this condition.

- For a patient with natural immunity from prior exposure to hepatitis B (i.e., HB core antibody and HBS antibody positive and normal liver function tests), the panel recommends the same therapies as those without such findings as long as the patient’s viral load is monitored.

- For patients with chronic hepatitis B who are untreated, referral for antiviral therapy is appropriate prior to immunosuppressive therapy.
Hepatitis C
- In patients with established RA with moderate or high disease activity and evidence of chronic hepatitis C virus (HCV) infection, who are receiving or have received effective antiviral treatment, the panel conditionally recommends treating them the same as the patients without this condition.
- The panel recommends that rheumatologists work with gastroenterologists and/or hepatologists who would monitor patients and reassess the appropriateness of antiviral therapy. This is important considering the recent availability of highly effective therapy for HCV, which may lead to a greater number of HCV patients being treated successfully.
- If the same patient is not requiring or receiving antiviral treatment for their hepatitis C, the panel conditionally recommends using DMARD therapy rather than TNFi.

Malignancy
Previous Melanoma and Non-Melanoma Skin Cancer
- In patients with established RA and moderate or high disease activity and a history of previously treated or untreated skin cancer (melanoma or non-melanoma), the panel conditionally recommends the use of DMARD therapy over biologics or tofacitinib.

Previous Lymphoproliferative Disorders
- In patients with established RA with moderate or high disease activity and a history of a previously treated lymphoproliferative disorder, the panel strongly recommends using rituximab rather than a TNFi and conditionally recommends using combination DMARD therapy, abatacept or tocilizumab rather than TNFi.

Previous Solid Organ Cancer
- In patients with established RA with moderate or high disease activity and previously treated solid organ cancer, the panel conditionally recommends that they be treated for RA just as one would treat an RA patient without a history of solid organ cancer.

Serious Infections
- In patients with established RA with moderate or high disease activity and previous serious infection(s), the panel conditionally recommends using combination DMARD therapy or abatacept rather than TNFi.

Juvenile Idiopathic Arthritis
The 2011 American College of Rheumatology (ACR) Recommendations for the Treatment of Juvenile Idiopathic Arthritis include abatacept.2

For JIA Patients with History of Arthritis of 5 or More Joints
- Initiation of abatacept was recommended as one treatment approach for patients who have received a TNFα inhibitor for 4 months and have high disease activity, irrespective of features of poor prognosis, or moderate disease activity and features of poor prognosis (level B).
- Initiation of abatacept was recommended as one treatment approach for patients who have received more than one TNFα inhibitor sequentially and have moderate or high disease activity, irrespective of poor prognostic features, or low disease activity with features of poor prognosis (level B).

For JIA Patients with Systemic Arthritis with Active Arthritis (and without Active Systemic Features)
- Initiation of abatacept was recommended for patients who have received methotrexate and a TNFα inhibitor and have high disease activity, irrespective of features of poor prognosis, or have moderate disease activity and poor prognostic features (level B).

The 2013 update to the 2011 ACR recommendations includes the use of abatacept in those patients with systemic JIA with continued disease activity and synovitis.20

For Patients with Systemic JIA with Active Systemic Features and Varying Degrees of Synovitis
- Use of abatacept was recommended only for patients with an MD global ≥5 and an AJC >4 after a trial of both an interleukin-1 (IL-1) inhibitor and tocilizumab (sequentially) (level D). Use of abatacept for patients with an AJC of 0 irrespective of the MD global was inappropriate (level D), with the exception of patients who had tried both an IL-1 inhibitor and tocilizumab (sequentially), in which case it was uncertain. Use of abatacept for patients with an MD global <5 and an AJC ≥0 or an MD global ≥5 and an AJC <4 was inappropriate (level D), with the exception of patients who had tried both an IL-1 inhibitor and tocilizumab (sequentially) or a disease-modifying antirheumatic drug (DMARD) plus either an IL-1 inhibitor or tocilizumab, in which case it was uncertain. Use of abatacept for patients with an MD global ≥5 and an AJC >4 was inappropriate (level D), with the exception of patients who had tried both an IL-1 inhibitor and tocilizumab (sequentially), in which case it was appropriate (level D), or patients who had tried a DMARD plus either an IL-1 inhibitor or tocilizumab, in which case it was uncertain.
For Patients with Systemic JIA without Active Systemic Features and Varying Degrees of Active Synovitis
• Use of abatacept was recommended for patients with an AJC >0 after treatment with MTX or leflunomide (level B), anakinra (level D), or tocilizumab (level D).

For Patients with Systemic JIA with Features Concerning for Macrophage Activation Syndrome (MAS)
• Initiation of abatacept was inappropriate (level D).

Level of evidence "B" was assigned when the recommendation was supported by nonrandomized controlled studies (e.g., cohort and case–control studies) or extrapolations from randomized clinical trials.

Level of evidence "C" was assigned when the recommendation was supported by uncontrolled studies (case series) extrapolations from nonrandomized controlled studies, or marked extrapolations from randomized clinical trials (e.g., studies of adult arthritis patients applied to juvenile arthritis or studies of polyarthritis phenotype applied to oligoarthritis).

Level of evidence "D" was assigned when the recommendation was based upon expert opinion.

REFERENCES

The foregoing Oxford policy has been adapted from an existing UnitedHealthcare Pharmacy Clinical Pharmacy Program that was researched, developed and approved by the UnitedHealth Group National Pharmacy & Therapeutics Committee. [2017D0039I]


**POLICY HISTORY/REVISION INFORMATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/01/2017</td>
<td>Revised coverage rationale:</td>
</tr>
<tr>
<td></td>
<td>o Added language to indicate Orencia is proven and medically necessary for the treatment of psoriatic arthritis when all of the following criteria are met:</td>
</tr>
<tr>
<td></td>
<td>▪ Diagnosis of active psoriatic arthritis (PsA); and</td>
</tr>
<tr>
<td></td>
<td>▪ Orencia is initiated and titrated according to U.S. Food and Drug Administration labeled dosing for psoriatic arthritis up to a maximum of (or equivalent dose and interval schedule):</td>
</tr>
<tr>
<td></td>
<td>- 500mg every 4 weeks for patients weighing &lt;60kg</td>
</tr>
<tr>
<td></td>
<td>- 750mg every 4 weeks for patients weighing 60kg to 100kg</td>
</tr>
<tr>
<td></td>
<td>- 1,000mg every 4 weeks for patients weighing &gt;100kg and</td>
</tr>
<tr>
<td></td>
<td>▪ Patient is not receiving Orencia in combination with any of the following:</td>
</tr>
<tr>
<td></td>
<td>- Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]</td>
</tr>
<tr>
<td></td>
<td>- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]</td>
</tr>
<tr>
<td></td>
<td>- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]</td>
</tr>
<tr>
<td></td>
<td>o Removed language indicating Orencia is unproven and not medically necessary for the treatment of psoriatic arthropathy</td>
</tr>
<tr>
<td></td>
<td>▪ Updated list of applicable ICD-10 diagnosis codes; added L40.50, L40.51, L40.52, L40.53, L40.54, and L40.59</td>
</tr>
<tr>
<td></td>
<td>▪ Updated supporting information to reflect the most current background information, clinical evidence, FDA information, and references</td>
</tr>
<tr>
<td></td>
<td>▪ Archived previous policy version PHARMACY 199.12 T2</td>
</tr>
</tbody>
</table>